BRAINTEASER mid-term workshop took place on 28 February 2023 in the prestigious location of the University of Padua Botanical Garden, Italy and was attended by almost 80 participants. Our integrated members Helena Aidos and Sara C. Madeira, together with Andreia Martins, attended and contributed to the discussion of the halfway project achievements.
The organization of the event came at the end of the first phase of the project and served as the basis for the launch of the second phase or ‘pilot phase’, which focuses on transforming the current approach to health from a reactive to a predictive system focused on risk forecast, patient stratification and prognosis:
“The BRAINTEASER project, which arrived at half of its path, is providing innovative approaches to the home care of persons with ALS, while supporting and reassuring caregivers in daily life. Providing innovative, cost-effective, and flexible technological devices for a continuous assessment of patients will allow strict attention to patient’s needs and to their physical and psychological problems and strict and continuous control of their clinical status. In addition, during the project, a wealth of data is being collected. These data will be analyzed with the most advanced techniques of artificial intelligence, allowing a better understanding of the heterogeneity of the disease progression. In summary, BRAINTEASER has the potential to offer novel instruments aimed at modifying for better the quality of life and the care of persons with ALS”.
BRAINTEASER is a project, funded by the European Horizon 2020 program, which intends to exploit the value of clinical data, completely anonymized and integrated with personal and environmental data collected through smartwatches and low-cost environmental sensors. BRAINTEASER uses this data to develop clinical software and mobile applications to support patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), their clinicians and families.
More info on BRAINTEASER, Twitter and LinkedIn.